YSB (SEHK:9885) Stock Undervalued Or Trapped By Thin Margins

YSB just reminded investors that earnings sentiment and share price can live in different worlds. The stock closed at HK$3.55, while trailing profit growth and a low P/E of 11.2x against Hong Kong healthcare peers present a more upbeat picture.

The headline today is profit quality. Net income over the past year is higher and margins are at 0.9% compared with 0.5% the prior year. The market is treating YSB like a problem stock, while the latest earnings frame this as a debate about how long that profit traction can last.

Is YSB at 11.2x P/E a rare mispricing, or is the HK$3.55 price exactly where it should be given recent margins and earnings quality? Compare that gap to the analyst DCF view with our valuation analysis for YSB

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): ¥10,283.053m vs. ¥9,842.619m (change of ¥440.434m)
• Net Income (Excl. Extra Items, H1 2026 vs. H1 2025): ¥110.837m vs. ¥78.117m (up 41.9%)
• Basic EPS (H1 2026 vs. H1 2025): ¥0.164 per share vs. ¥0.114557 per share (up 43.1%)
• Net Margin (Trailing 12 Months vs. Prior Year): 0.9% vs. 0.5% (margin level improved year on year)

Prefer clear visual charts instead of scanning dense earnings tables and margin figures for YSB? See the full picture of its valuation in an easy dashboard view through the company report for YSB.

YSB earnings signal improving platform resilience

For a bullish view on YSB, the latest earnings give some support. Revenue in H1 2026 is higher than H1 2025 and net income excluding extra items has risen alongside basic EPS. Margins on a trailing basis are also above the prior year at 0.9% compared with 0.5%. For a digital healthcare infrastructure story that leans on scale, these moves in profit and margin direction suggest the current model is holding together rather than stalling.

YSB risks remain around margin depth and volatility

For the cautious view, the numbers also leave room for concern. Net margin is still below 1%, which means small revenue or cost shocks can quickly affect earnings for YSB. The 90 day share price return has declined about 8%, which hints that investors are not yet convinced the recent earnings strength resolves medium term risks such as regulatory shifts or competition pressure across China digital healthcare.

Review whether YSB’s thin margins and recent insider selling hint at deeper structural fragility by reading the full risk analysis for YSB which shows 1 important warning sign.

Stay Ahead With YSB And Beyond

If YSB’s rising earnings, thin margins and recent share price pullback have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more attractive entry point. When you decide to take a position, keep a clear view of your holdings and filter out market noise with the Portfolio Command Center that highlights only the most important developments. For long term context and fresh angles on YSB and other stocks, tap into the Community to see how other investors are thinking about the same risks and catalysts. By surfacing potential triggers and warning signs early, Simply Wall St helps you act with confidence and stay ahead of the market.

Curious About Alternatives Worth Exploring

Some stocks are already building quiet momentum while others could be nearing a breakout. Fresh ideas do not stay under the radar for long, so consider exploring them soon.

• Spot potential turnaround leaders before they start flying by scanning the curated list of 614 high quality undiscovered gems while it still sits under most investors’ radar.
• Identify reliable income ideas that can steady a portfolio as rates and sentiment shift by reviewing the hand picked 434 dividend fortresses while yields still look appealing.
• Review companies involved in grid modernisation by checking the focused 39 power grid technology and infrastructure stocks before the story appears in every headline.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com